Option is a supplier of cellular gateways and a solution provider for the machine-to-machine (M2M) space. Co. has five operating segments: Devices & Solutions, which produces USB devices, routers as well as the end to end service offerings; M2M, which includes Co.'s device, called CloudGate; Embedded & Solutions, which is engaged in the production of embedded devices or module offerings and associated integration and certification services; License, which relates to license deals, closed with third parties; and Other, which includes the connection manager software business and mobile security solutions.
Floridienne SA is a Belgium-based company engaged in the chemicals, gourmet food and life sciences sectors. The Chemicals division is engaged in two areas: additives for plastics used for stabilizing Polyvinyl Chloride and fireproofing plastics, as well as the recycling of nickel-cadmium, nickel-metal hydride and lithium-ion batteries. The Life Sciences division is active in the production and marketing of natural technologies and products that offer green and sustainable alternatives in agriculture, hygiene products and healthcare, among others. The Life Sciences division also provides plant proteases and integrated pest management. The Gourmet Food division is engaged in the production and marketing of party and gourmet food products such as snails, scallops, stuffed shellfish, smoked salmon, seafood salads, aperitif snacks and ethnic dishes. The Gourmet Food division also operates in the field of special needs foods, such as for people with deglutition problems, among others.
UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.